Department of Endocrinology, Diabetes and Genetics, University Children's Hospital, Medical University - Sofia, Bulgaria.
Central Clinical Laboratory, Alexandrovska Hospital, Medical University - Sofia, Bulgaria.
Pediatr Diabetes. 2020 Feb;21(1):88-97. doi: 10.1111/pedi.12930. Epub 2019 Oct 27.
There is a need for a non-invasive, affordable, and reliable method for bone health screening in pediatric patients at risk.
To assess Bone Health Index (BHI) in pediatric patients with type 1 diabetes (T1D) and its relation to bone metabolism, age at onset, duration, control, and insulin dose.
Left-hand radiographs were obtained from 65 patients with T1D, mean age 11.23 ± 3.89 years, mean disease duration 5.23 ± 3.76 years and mean glycosylated hemoglobin (HbA1c)-83 mmol/mol (9.7%). Blood and 24 hours urine samples were collected for bone and mineral metabolism assessment. BoneXpert was used to determine BHI, Bone Health Index standard deviation score (BHI SDS), and bone age.
Mean BHI SDS was -1.15 ± 1.19 (n = 54). In 20.37% (n = 11) BHI SDS was < -2SD with mean value -2.82 ± 0. 69, P < .001. These patients had lower levels of beta cross laps (0.77 ± 0.33 ng/mL vs 1.17 ± 0.47 ng/mL), osteocalcin (47.20 ± 14.07 ng/mL vs 75.91 ± 32.08 ng/mL), serum magnesium (0.79 ± 0.05 mmol/L vs 0.83 ± 0.06 mmol/L) and phosphorus (1.48 ± 0.29 mmol/L vs 1.71 ± 0.28 mmol/L) but higher ionized calcium (1.29 ± 0.04 mmol/L vs 1.26 ± 0.05 mmol/L), P < .05, compared to patients with BHI SDS in the normal range. We found a positive correlation between BHI SDS and age at manifestation (r = 0.307, P = 0.024) and a negative one with disease duration (r = -0.284, P = .038). No correlations were found with HbA1c, insulin dose, height, weight, BMI.
To the best of our knowledge, this is the first study to assess bone health in pediatric patients with T1D using BHI. We found significantly decreased cortical bone density and bone turnover in 20.37%. Earlier age at onset and diabetes duration may have a negative impact on cortical bone density in patients with poor control. Longitudinal studies are needed to follow changes or to assess future interventions.
需要一种非侵入性、经济实惠且可靠的方法来筛查有风险的儿科患者的骨骼健康。
评估 1 型糖尿病(T1D)患儿的骨骼健康指数(BHI)及其与骨代谢、发病年龄、病程、控制情况和胰岛素剂量的关系。
从 65 名 T1D 患儿中获取左手 X 光片,平均年龄 11.23±3.89 岁,平均病程 5.23±3.76 年,平均糖化血红蛋白(HbA1c)-83mmol/mol(9.7%)。采集血液和 24 小时尿液样本进行骨矿物质代谢评估。使用 BoneXpert 确定 BHI、BHI 标准差评分(BHI SDS)和骨龄。
平均 BHI SDS 为-1.15±1.19(n=54)。20.37%(n=11)的 BHI SDS<-2SD,平均值为-2.82±0.69,P<0.001。这些患者的β交联胶原(β cross laps)水平较低(0.77±0.33ng/mL 比 1.17±0.47ng/mL),骨钙素(47.20±14.07ng/mL 比 75.91±32.08ng/mL)、血清镁(0.79±0.05mmol/L 比 0.83±0.06mmol/L)和磷(1.48±0.29mmol/L 比 1.71±0.28mmol/L)水平较低,但离子钙(1.29±0.04mmol/L 比 1.26±0.05mmol/L)水平较高,P<0.05,与 BHI SDS 正常范围的患者相比。我们发现 BHI SDS 与发病年龄呈正相关(r=0.307,P=0.024),与病程呈负相关(r=-0.284,P=0.038)。与 HbA1c、胰岛素剂量、身高、体重、BMI 无相关性。
据我们所知,这是第一项使用 BHI 评估 T1D 儿科患者骨骼健康的研究。我们发现皮质骨密度和骨转换明显降低的比例为 20.37%。较早的发病年龄和病程可能对控制不佳的患者的皮质骨密度产生负面影响。需要进行纵向研究以跟踪变化或评估未来的干预措施。